MedTrace Logo

Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

NCT03793712 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2020-09-23

No results posted yet for this study

Summary

A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia

Conditions

Interventions

DRUG

Lu AF11167 (1-2 mg/day)

Fixed-flexible oral dose, tablets. Once daily. 12 weeks.

DRUG

Lu AF11167 (3-4 mg/day)

Fixed-flexible oral dose, tablets. Once daily. 12 weeks.

DRUG

Placebo

Placebo oral dose, tablets. Once daily. 12 weeks.

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-27
Primary Completion
2020-08-20
Completion
2020-09-03

Countries

  • Bulgaria
  • Czechia
  • Estonia
  • Germany
  • Hungary
  • Latvia
  • Poland
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03793712 on ClinicalTrials.gov